证券代码:002880 证券简称:卫光生物 公告编号:2025-050 深圳市卫光生物制品股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1.股东会届次：2025 年第三次临时股东会。 2.股东会的召集人：公司董事会。 3.本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关 规定。 4.会议时间： （4）根据相关法规应当出席股东会的其他人员。 8.会议地点：广东省深圳市光明区光明街道光侨大道 3402 号办公楼 4 楼会 议室。 二、会议审议事项 本次股东会审议事项如下： （1）现场会议时间：2025 年 11 月 27 日 14:30。 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 27 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交 ...

深圳市卫光生物制品股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市卫光生物制品股份有限公司（以下简称公司）第四届董事会第五次会 议于2025年11月11日，在公司办公楼四楼会议室以现场结合通讯的方式召开。本 次会议应参加董事9名，实际参加董事9名，公司高级管理人员列席了会议。本次 会议由董事长张战先生主持，会议的召集、召开和表决程序符合《公司法》等有 关法律、法规及《公司章程》的规定。 二、董事会会议审议情况 会议经逐项审议，书面表决，审议通过了以下议案： 1.审议通过了《关于聘任董事会秘书的议案》; 本议案经提名委员会审议通过后，提交董事会审议。 证券代码:002880 证券简称:卫光生物 公告编号:2025-047 公司董事会经审议同意续聘大信会计师事务所（特殊普通合伙）为公司 2025 年度审计机构，聘期 1 年，负责公司 2025 年年报审计及内控审计工作，费用总 共为 76 万元（不含差旅费）。 具体内容详见同日刊登在指定信息披露媒体及巨潮资讯网(www.cninfo.com ...

Core Viewpoint - The company, Shenzhen Weiguang Biological Products Co., Ltd., has released its third-quarter financial report, ensuring the accuracy and completeness of the information disclosed, with no significant omissions or misleading statements [2][3]. Financial Data Summary - The third-quarter financial report has not been audited [6]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. Shareholder Information - The report includes details on the total number of common shareholders and the shareholding situation of the top ten shareholders [5]. - There are no changes in the share lending situation of the top ten shareholders compared to the previous period [5]. Other Important Matters - The report includes the consolidated balance sheet and profit statement for the period from the beginning of the year to the end of the reporting period [4][6].

Core Viewpoint - Weigao Bio (002880.SZ) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating income of 791 million yuan, representing a year-on-year decrease of 7.40% [1] - The net profit attributable to shareholders was 158 million yuan, down 13.60% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 155 million yuan, a decrease of 12.67% year-on-year [1] - Basic earnings per share stood at 0.696 yuan [1]

Core Insights - The company reported a revenue of 791 million yuan for the first three quarters of 2025, representing a year-on-year decline of 7.40% [1] - The net profit attributable to shareholders of the listed company was 158 million yuan, down 13.60% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 155 million yuan, reflecting a year-on-year decrease of 12.67% [1]

Core Viewpoint - Weigao Bio is a significant player in the domestic blood products sector, focusing on the production and research of blood products, with a strong technical barrier and a diverse product line [1] Group 1: Business Performance - In Q3 2025, Weigao Bio reported revenue of 791 million, ranking 5th in the industry, with the top competitor, Shanghai Raas, generating 6.091 billion [2] - The company's net profit for the same period was 158 million, also ranking 5th, while the industry leader reported a net profit of 1.47 billion [2] Group 2: Financial Ratios - As of Q3 2025, Weigao Bio's debt-to-asset ratio was 30.56%, higher than the industry average of 28.01% [3] - The gross profit margin for Q3 2025 was 42.47%, which is below the industry average of 44.76% [3] Group 3: Executive Compensation - The chairman, Zhang Zhan, received a salary of 1.2442 million in 2024, an increase of 21,600 from 2023 [4] - The general manager, Guo Caiping, also received a salary of 1.2442 million in 2024, up by 33,800 from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.70% to 12,500, while the average number of shares held per shareholder increased by 0.70% to 18,100 [5] - Hong Kong Central Clearing Limited became a new major shareholder, holding 679,400 shares [5] Group 5: Future Outlook - Huazheng Securities predicts that Weigao Bio will achieve revenue and profit growth in 2024, with a notable increase in non-recurring net profit [5] - The company is expected to see revenue of 1.347 billion, 1.497 billion, and 1.653 billion from 2025 to 2027, with net profits of 299 million, 345 million, and 396 million respectively [5] - Zhongyou Securities anticipates steady growth in 2024, with a recovery in blood product business expected [6]

Core Viewpoint - Weigao Bio released its third-quarter report, indicating a decline in both revenue and net profit compared to the previous year [1]. Financial Performance - The company's revenue for the first three quarters amounted to 790,899,107.60 yuan, representing a year-on-year decrease of 7.4% [1]. - The net profit attributable to shareholders of the listed company was 157,860,537.25 yuan, which is a year-on-year decrease of 13.6% [1]. Shareholder Changes - Among the top ten circulating shareholders, new entrants include Shenzhen Weigao Biological Products Co., Ltd. - Phase III Employee Stock Ownership Plan, Hong Kong Central Clearing Limited, and Nie Haiyan [1].

Core Insights - The company reported a decline in revenue and net profit for the third quarter and the first three quarters of the year [1] Financial Performance - In Q3, the company achieved revenue of 273 million yuan, a year-on-year decrease of 17.63% [1] - The net profit attributable to shareholders for Q3 was 50.21 million yuan, down 31.06% year-on-year [1] - For the first three quarters, the company recorded revenue of 791 million yuan, a decline of 7.40% year-on-year [1] - The net profit attributable to shareholders for the first three quarters was 158 million yuan, reflecting a decrease of 13.60% year-on-year [1]

Group 1 - The company's Q3 revenue is 273 million, a decrease of 17.63% [1] - The net profit for Q3 is 50.21 million, down 31.06% [1] - The revenue for the first three quarters is 791 million, a decline of 7.40% [1] Group 2 - The net profit for the first three quarters is 158 million, a decrease of 13.60% [1]

Financial Performance - The company's revenue for Q3 2025 was ¥272,803,789.48, a decrease of 17.63% compared to the same period last year[5] - Net profit attributable to shareholders was ¥50,214,191.78, down 31.06% year-over-year[5] - The basic earnings per share decreased to ¥0.2214, reflecting a decline of 31.06% compared to the previous year[5] - Total operating revenue for the current period was CNY 790,899,107.60, a decrease of 7.4% from CNY 854,101,695.51 in the previous period[17] - Net profit for the current period was CNY 157,817,918.30, a decline of 13.5% compared to CNY 182,526,379.42 in the previous period[18] - Earnings per share (EPS) for the current period was CNY 0.6960, down from CNY 0.8056 in the previous period[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,394,096,344.18, an increase of 2.93% from the end of the previous year[5] - Total assets increased to CNY 3,394,096,344.18, compared to CNY 3,297,444,233.19 in the previous period, reflecting a growth of 2.9%[16] - Total liabilities decreased to CNY 1,037,403,561.90, down from CNY 1,053,207,768.02, a reduction of 1.5%[16] - Total equity attributable to shareholders increased to CNY 2,323,925,868.39, up from CNY 2,211,425,331.14, representing a growth of 5.1%[16] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥91,120,401.29, down 9.76% compared to the same period last year[5] - Operating cash inflow for the current period was CNY 842,667,774.40, an increase of 3.5% from CNY 814,550,758.10 in the previous period[19] - Net cash flow from operating activities decreased to CNY 91,120,401.29, down 10.8% from CNY 100,979,444.84 in the previous period[19] - Cash outflow from investing activities totaled CNY 389,923,297.69, compared to CNY 202,871,023.87 in the previous period, indicating a significant increase in investment spending[20] - Net cash flow from investing activities was -CNY 225,188,536.58, worsening from -CNY 202,739,405.97 in the previous period[20] - Cash inflow from financing activities decreased to CNY 131,067,909.27, down 46.0% from CNY 243,023,091.82 in the previous period[20] - Net cash flow from financing activities was -CNY 61,095,218.93, a decline from CNY 106,122,041.96 in the previous period[20] - The ending cash and cash equivalents balance was CNY 79,567,082.84, a decrease from CNY 255,807,762.34 in the previous period[20] Investments and Shareholder Information - The company received government subsidies amounting to ¥1,515,280.00 during the reporting period[7] - The number of ordinary shareholders at the end of the reporting period was 12,496[10] - The largest shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of the shares[10] - The company reported a significant increase in investment income, rising to ¥3,152,675.52, a 2708.23% increase compared to the previous year[9] - The company reported an investment income of CNY 3,152,675.52, compared to a loss of CNY 120,874.33 in the previous period[17] - The company plans to participate in a land auction for the smart industry base project, with significant developments expected in 2025[12] - The company is set to issue A-shares to specific investors in October 2025, aiming to enhance capital structure[12] Asset Composition - The company's cash and cash equivalents decreased to ¥79,599,872.52 from ¥274,763,226.74, representing a decline of approximately 71%[14] - Accounts receivable increased to ¥175,464,371.34 from ¥132,861,636.40, showing a growth of about 32%[14] - Inventory rose significantly to ¥966,635,488.07 from ¥793,462,099.62, indicating an increase of approximately 22%[14] - Total current assets decreased to ¥1,345,357,063.60 from ¥1,527,590,386.50, reflecting a decline of around 12%[14] - Non-current assets, including investment properties, increased to ¥869,342,520.53 from ¥800,940,962.12, marking a growth of about 8.6%[14] - The company reported a notable increase in prepayments to ¥6,394,700.16 from ¥2,133,760.33, which is an increase of approximately 200%[14] - The company’s long-term intangible assets rose to ¥152,383,603.43 from ¥134,911,011.12, reflecting an increase of about 12.9%[14] - The company’s goodwill remained stable at ¥19,230,057.19, indicating no change during the reporting period[14] Research and Development - Research and development expenses for the current period were CNY 35,629,988.19, a decrease of 6.5% from CNY 38,106,155.61[17] - Deferred tax assets increased to CNY 10,465,681.38 from CNY 9,969,591.92, indicating a growth of 5.0%[15]